Last updated on August 2019

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC


Brief description of study

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Clinical Study Identifier: NCT02273375

Find a site near you

Start Over

Austin Hospital

Heidelberg, Australia
3.44miles
  Connect »

St. Vincent's Hospital

Fitzroy, Australia
4.05miles
  Connect »

Epworth HealthCare - Richmond

Richmond, Australia
5.55miles
  Connect »